Literature DB >> 15257865

Combined antihypertensive and lipid-lowering treatment.

Maurizio Cesari1, Achille C Pessina.   

Abstract

Hypertension and hypercholesterolemia are frequently associated, and their treatment is proven to reduce cardiovascular risk. Current guidelines on cardiovascular prevention strongly recommend treating both disorders. Unfortunately, the low treatment and control rates, combined with the high prevalence of both conditions, still contribute to the high burden of cardiovascular disease in Western countries. In the past 5 years, many studies evaluating the benefit of combined antihypertensive and lipid-lowering treatment on endothelial dysfunction, coronary atherosclerosis, hypertension control, and on primary and secondary prevention of cardiovascular events have been published. In this article, we discuss and critically evaluate the available evidence on the potential benefits of combined antihypertensive and lipid-lowering treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15257865     DOI: 10.1007/s11906-004-0025-5

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  54 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

2.  A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats.

Authors:  Tomoya Yamashita; Seinosuke Kawashima; Yoichi Miwa; Masanori Ozaki; Masayuki Namiki; Tetsuaki Hirase; Nobutaka Inoue; Ken-ichi Hirata; Mitsuhiro Yokoyama
Journal:  J Hypertens       Date:  2002-12       Impact factor: 4.844

3.  Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease.

Authors:  M Vasa; S Fichtlscherer; K Adler; A Aicher; H Martin; A M Zeiher; S Dimmeler
Journal:  Circulation       Date:  2001-06-19       Impact factor: 29.690

4.  Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin.

Authors:  A N Orekhov; V V Tertov; I A Sobenin; N M Akhmedzhanov; E M Pivovarova
Journal:  Int J Cardiol       Date:  1997-12-31       Impact factor: 4.164

5.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.

Authors:  G O'Driscoll; D Green; R R Taylor
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

6.  Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease.

Authors:  Sergio Mondillo; Piercarlo Ballo; Riccardo Barbati; Francesco Guerrini; Tiziana Ammaturo; Eustachio Agricola; Monica Pastore; Francesco Borrello; Mirko Belcastro; Andrea Picchi; Renato Nami
Journal:  Am J Med       Date:  2003-04-01       Impact factor: 4.965

7.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

8.  Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension.

Authors:  Kathryn E Ferrier; Michael H Muhlmann; Jean Philippe Baguet; James D Cameron; Garry L Jennings; Anthony M Dart; Bronwyn A Kingwell
Journal:  J Am Coll Cardiol       Date:  2002-03-20       Impact factor: 24.094

9.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  3 in total

1.  Effects of Single Pill Combinations Compared to Identical Multi Pill Therapy on Outcomes in Hypertension, Dyslipidemia and Secondary Cardiovascular Prevention: The START-Study.

Authors:  Thomas Wilke; Burkhard Weisser; Hans-Georg Predel; Roland Schmieder; Sven Wassmann; Anton Gillessen; Jörg Blettenberg; Ulf Maywald; Olaf Randerath; Sabrina Mueller; Michael Böhm
Journal:  Integr Blood Press Control       Date:  2022-02-27

2.  Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin.

Authors:  Chia-Hao Chen; Yow-Shieng Uang; Shang-Ta Wang; Jyh-Chin Yang; Chun-Jung Lin
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-14       Impact factor: 2.629

3.  Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.

Authors:  Benjamin Wolozin; Stanley W Wang; Nien-Chen Li; Austin Lee; Todd A Lee; Lewis E Kazis
Journal:  BMC Med       Date:  2007-07-19       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.